<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616057</url>
  </required_header>
  <id_info>
    <org_study_id>2007/21/NOV/300</org_study_id>
    <secondary_id>B40320072930</secondary_id>
    <nct_id>NCT00616057</nct_id>
  </id_info>
  <brief_title>Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome</brief_title>
  <acronym>FRUCTOB</acronym>
  <official_title>Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is constantly increasing, causing an important risk to develop diseases such as heart
      disease, diabetes,... Some recent studies have shown that obese people present modifications
      of colon microflora and a low-grade inflammation.

      In our laboratory, we have demonstrated that the intake of fructans lessens dietary intake,
      body weight gain, adipose tissue accumulation and steatosis in rodents. These effects lead to
      an improvement of insulin resistance and hyperglycemia in diabetic rats and mice. Fructans
      are also able to restore the microflora disturbed by a high fat diet and to prevent
      endotoxemia. Moreover, studies have shown that fructans intake promotes satiety (Cani et al,
      Diabetes 2007) and or decreases fat mass (Abrams et al, Journal of Pediatrics 2007) in
      healthy human. An intervention study in obese patients is thus needed to study the effects of
      fructans in the target population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gut microbiota composition</measure>
    <time_frame>3 months</time_frame>
    <description>HITChip analysis (phylogenetic profiling by DNA microarray)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut microbial-related metabolites (in urine and plasma)</measure>
    <time_frame>3 months</time_frame>
    <description>NMR spectroscopic analysis of urine and plasma metabolic profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic parameters (weight, BMI, glycemia, fat mass,...)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin, non digestible carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fructans, non digestible carbohydrates fermented in the caeco-colon</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synergy 1</intervention_name>
    <description>8 grams/day during the first week and then 8 grams twice a day during 3 months</description>
    <arm_group_label>A</arm_group_label>
    <other_name>inulin</other_name>
    <other_name>oligofructose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>maltodextrin</intervention_name>
    <description>8 grams/day during the first week and then 8 grams twice a day during 3 months</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI&gt;30 kg/m2

        Exclusion Criteria:

          -  acute or chronic evoluting disease

          -  alcohol consumption &gt; 30 units/week

          -  more than 30 minutes of sports 3 times/week

          -  usual consumption of pre/probiotics or fibers supplement

          -  recent consumption of antibiotics

          -  slimming diet or unusual diet

          -  pregnant women

          -  anti-diabetics drugs ou slimming drugs

          -  previous bariatric surgery

          -  severe oesophagus reflux
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thissen Jean-Paul</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <state>Branbant Wallon</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fructans supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

